gut and vasculature in the OrganoPlate ® - a high throughput microfluidic
tissue culture platform.
transition from 2D to 3D cell culture is a first step towards more
physiologically relevant in vitro models for human (disease)
modeling. To adequately capture the complex tissue architectures
observed in vivo, 3D microfluidic techniques incorporate and achieve
long-term gradient stability, continuous perfusion and patterning of cell
layers as stratified co-cultures.
Mimetas develops Organ-on-a-Chip-based models for disease modeling and
evaluation of new medicines. Our unique microfluidic technology – the
OrganoPlate – enables testing of compounds on miniaturized 3D organ
models in high-throughput. These models are expected to show better
physiological relevance versus conventional 2D cell culture models,
without compromising throughput or ease of use. Combining these models
with advanced and powerful imaging techniques really opens up a whole new
panel of assays that researchers can use to get concrete answers to their
questions very, very quickly and in a robust and scalable manner. This
presentation provides an overview of the technology and its applications
for gut and vasculature modeling.
Chiwan is a Scientist in the Model Development team at Mimetas where she
develops 3D CNS on-a-chip models. She received her master’s degree in
Biomedical Sciences at the University of Groningen (The Netherlands).
Her main interest during the bachelor’s degree was Immunology, where she
gained research experience at the Weatherall Institute of Molecular
Medicine, University of Oxford. During her master’s she focused on
research in Neuroscience, the aim of her dissertation was to assess the
role of astrocytes in axonal damage in Vanishing White Matter disease at
the VU University Medical Center Amsterdam. Besides, she investigated
the role of microglia in Glioblastoma by isolating cells from patient’s
tumor material at the University Medical Centre of Groningen. At Mimetas
she developed an 3D CNS model for high-throughput neurotoxicity and
seizure liability testing. In addition, she focusses on developing 3D
Parkinson’s disease model for screening of novel drug candidates.